Neumora Therapeutics, Inc. (NMRA) Stock Price & Analysis
Neumora Therapeutics, Inc. (NMRA) closed at USD 0.43 on Thursday, October 15, 2026, up 20.45% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.35; the Oct 15, 2026 session ranged USD 0.36–0.46 on volume of 6,363,455 shares. Market capitalization is $80.23M, with a 52-week range of USD 0.32–3.65 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NMRA.md
Key facts (NMRA)
- Analysts: Buy (mean 2.22 on a 1–5 scale) (9 analysts), mean target USD 6.14 (range 3–14).
- Total return with dividends: 1Y -76.0% vs S&P 500 +18.1%; 5Y -97.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.19, revenue estimate $0K.
Analysts (NMRA)
Consensus Buy (mean 2.22 on a 1–5 scale), 9 analysts; mean target USD 6.14 (low 3, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-13 | RBC Capital | Target lowered | Outperform | $7 → $5 |
| 2026-06-18 | Mizuho | Target lowered | Outperform | $6 → $4 |
Total return (dividends reinvested) (NMRA)
| 1Y (from 2025-10-16) | 5Y (from 2023-09-11) | |
|---|---|---|
| Total return | -76.0% | -97.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -76.1% | -69.1% |
| Volatility (annualized) | 128.2% | 135.6% |
| Max drawdown | -90.1% (Feb 2026→Oct 2026) | -97.8% (Feb 2024→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 0.43 |
|---|---|
| Change | ▲ 20.45% (up) |
| Previous Close | USD 0.35 |
| Open | USD 0.37 |
| Day Range | USD 0.36 – 0.46 |
| 52-Week Range | USD 0.32 – 3.65 |
| Volume | 6,363,455 shares |
| Market Cap | $80.23M |
| Exchange | NMS |
Technical Analysis (NMRA)
Nexqual's technical model rates NMRA "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 23.41 (oversold) |
| vs SMA50 | Below (USD 1.06) |
| MACD | -0.19 (negative) |
Analyst Ratings (NMRA)
Wall Street analysts rate NMRA "Buy" based on 9 analysts, with a mean price target of USD 6.14 (range USD 3–14), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 6.14 |
| High Target | USD 14 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 7 / 1 / 1 |
Earnings (NMRA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.23 vs est -0.24 ▲ beat |
| 2026-03-31 | USD -0.3 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.35 vs est -0.33 ▼ miss |
| 2025-09-30 | USD -0.35 vs est -0.34 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (NMRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -187.11% |
| Debt / Equity | 1.2 |
| Current Ratio | 4.5 |
| Total Cash | $116.83M |
| Total Debt | $53.25M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (NMRA)
Nexqual rates Neumora Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $117M cash vs $53M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$181M (TTM) |
| Efficiency | Critical — ROE -187%, ROA -73.9% |
Ownership (NMRA)
| Insider Ownership | +23.08% |
|---|---|
| Institutional Ownership | +60.16% |
| Shares Outstanding | 187.90M |
| Float | 116.36M |
| Short % of Float | +6.09% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (NMRA)
Neumora Therapeutics, Inc. is led by Joshua Pinto (age 40), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO & Director | Joshua Pinto (age 40) |
|---|---|
| Executive Chairman | Paul L. Berns (age 58) |
| CFO & Principal Accounting Officer | Michael Lee Milligan (age 52) |
| Chief Scientific Officer | Nicholas Brandon (age 50) |
| Senior Vice President & Head of Quality | David Phillips |
Major Backers & Investors (NMRA)
Notable institutional backers of Neumora Therapeutics, Inc. include Siren, L.L.C., Softbank Group Corporation, MIC Capital Management UK LLP, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Siren, L.L.C. | 4.52% |
| Softbank Group Corporation | 3.24% |
| MIC Capital Management UK LLP | 2.37% |
| FMR, LLC | 1.86% |
| Wellcome Trust Ltd (the) As Trustee Of The Wellcome Trust | 1.76% |
| ICONIQ Capital, LLC | 1.36% |
| Two Sigma Investments, LP | 1.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.43% |
| Vanguard Group | 4.92% |
| Geode Capital | 1.39% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt